Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03570021 | ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer(ESTIMABL3) | active not recruiting | Phase 3 | 352 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | recruiting | Phase 3 | 593 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2026 |
| clinicaltrials |
| NCT07327216 | Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 180 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06554652 | Selective Neck Dissection Versus Modified Neck Dissection in PTC | recruiting | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06558981 | Adjuvant Radiotherapy in High Risk Locally Advanced DTC | recruiting | Phase 3 | 124 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07402538 | Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 184 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07385079 | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 412 | Sun Yat-sen UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07373990 | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 418 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | recruiting | Phase 3 | 300 | Man HuOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | recruiting | Phase 3 | 346 | Ming-Yuan ChenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06860971 | A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma | recruiting | Phase 3 | 144 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC(INCIPT-NPC) | recruiting | Phase 3 | 462 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | recruiting | Phase 3 | 166 | Ming-Yuan ChenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07154069 | Adaptive Immunotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 802 | Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248670 | Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC | active not recruiting | Phase 3 | 252 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07238569 | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 516 | Sun Yat-sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT05999630 | Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer | recruiting | Phase 3 | 100 | Vanderbilt University Medical CenterOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT06241612 | Individualized Elective Neck Irradiation in NPC Patients | recruiting | Phase 3 | 470 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04384627 | Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy(NPC-GTV) | active not recruiting | Phase 3 | 445 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07072000 | Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity | not yet recruiting | Phase 3 | 550 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04907370 | PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma(DIAMOND) | active not recruiting | Phase 3 | 532 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06228079 | Adjuvant vs Surgery Only in Early-stage Recurrent NPC | recruiting | Phase 3 | 176 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06749899 | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | recruiting | Phase 3 | 580 | Sun Yat-Sen University Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06957938 | Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma | not yet recruiting | Phase 3 | 168 | Fudan UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06912698 | Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma | recruiting | Phase 3 | 342 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04974398 | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 296 | AkesoINDUSTRY | 5 | Apr 13, 2025 | clinicaltrials |
| NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC(PROTECT-NPC) | recruiting | Phase 3 | 474 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06900218 | PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 664 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05304468 | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain | active not recruiting | Phase 3 | 452 | Sun Yat-sen UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06095154 | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05587374 | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)(GEMSTONE) | active not recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06775756 | Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 15, 2025 | clinicaltrials |
| NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 468 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. | recruiting | Phase 3 | 586 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 6, 2026source: clinicaltrials